EasyNAT BP/ DR Assay
Ongoing Challanges
- B.pertussis* infection (whooping cough) is highly contagious, primarily affecting infants and young children. It is clinically characterized by a gradually worsening cough that becomes paroxysmal and spasmodic, often followed by a high-pitched “whoop” upon inhalation, lasting up to 2-3 months.
- Macrolide antibiotics have long been the first-line treatment. The A2047G mutation in the 23S rRNA gene of *B. pertussis* is highly associated with macrolide resistance. Culture methods are difficult and time-consuming; serological methods are faster but lack sensitivity and specificity and cannot detect resistance.
Product Overview
The EasyNAT® BP/DR Assay is an automated, in vitro nucleic acid amplification test for the qualitative detection of *Bordetella pertussis* (BP) DNA and the A2047G mutation associated with macrolide resistance in human nasopharyngeal swab specimens.
Results obtained within 54 minutes
Designed to provide an accurate LOD: 500 copies/mL
Directly detects *B. pertussis* nucleic acid and the specific drug resistance gene in samples
Clinical Value
Dramatically improves the patient experience.
Provides correct guidance for antibiotic selection and prevention strategies.
Reduces the laboratory’s burden for screening.
Product Resources
EasyNAT® BP/ DR Assay
Brochure
EasyNAT® BP/ DR Assay
Instructions for Use
EasyNAT® BP/ DR Assay
SOP
